Aspirin (NSC 27223)

Catalog No.S3017 Synonyms: Acetylsalicylic acid, ASA

For research use only.

Aspirin (NSC 27223, Acetylsalicylic acid, ASA) is a salicylate, and irreversible COX1 and COX2 inhibitor, used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin induces autophagy and stimulates mitophagy.

Aspirin (NSC 27223) Chemical Structure

CAS No. 50-78-2

Selleck's Aspirin (NSC 27223) has been cited by 20 publications

Purity & Quality Control

Choose Selective COX Inhibitors

Other COX Products

Biological Activity

Description Aspirin (NSC 27223, Acetylsalicylic acid, ASA) is a salicylate, and irreversible COX1 and COX2 inhibitor, used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin induces autophagy and stimulates mitophagy.
Targets
COX2 [1] COX1 [1]
In vitro

Aspirin inhibits the activation of NF-kappa B, thus prevents the degradation of the NF-kappa B inhibitor, I kappa B, and therefore NF-kappa B is retained in the cytosol. Aspirin also inhibits NF-kappa B-dependent transcription from the Ig kappa enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells. [1] Aspirin and salicylate are mediated in part by their specific inhibition of IKK-beta, thereby preventing activation by NF-kappaB of genes involved in the pathogenesis of the inflammatory response. [2] Aspirin is protective against neurotoxicity elicited by the excitatory amino acid glutamate in rat primary neuronal cultures and hippocampal slices. [3] Aspirin triggers transcellular biosynthesis of a previously unrecognized class of eicosanoidsduring coincubations of human umbilical vein endothelial cells (HUVEC) and neutrophils [polymorphonuclear leukocytes (PMN)]. Aspirin evokes a unique class of eicosanoids formed by acetylated PGHS-2 and 5-lipoxygenase interactions. [4] Aspirin treatment inhibits the phosphorylation of IRS-1 at Ser307 as well as the phosphorylation of JNK, c-Jun, and degradation of IkappaBalpha in 3T3-L1 and Hep G2 cells treated with tumor necrosis factor (TNF)-alpha. Aspirin treatment inhibits phosphorylation of Akt and the mammalian target of rapamycin (but not extracellular regulated kinase or PKCzeta) in response to TNF-alpha. Aspirin rescues insulin-induced glucose uptake in 3T3-L1 adipocytes pretreated with TNF-alpha. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
AGS NW\odnhqTnWwY4Tpc44h[XO|YYm= NX7BS4R3OTVidH:gOlAhfW2xbD;MJIFnfGW{ MXexNkBpenN? NGn3OGRKdmirYnn0bY9vKG:oIFXzZ4hmemmlaHnhJINwdGlvc4TpcZVt[XSnZDDJUE05KHC{b3T1Z5Rqd25iaX6gbJVu[W5iQVfTJINmdGy|IHH0JFE2KHSxIE[wJJVud2xxTDDh[pRmeiBzMjDodpMh[nliRVzJV2E> NGC2UZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG1N|E5Oyd-MkCxOVMyQDN:L3G+
microglia cells MXrBcpRqdmW3cn;pcoZt[W2vYYTvdpkh[XO|YYm= M3PrSVE2KG2rboO= NIjLToRCdnSrbnX1do9qdm[uYX3tZZRwenliYXP0bZZqfHliaX6gUHBUNXO2aX31cIF1\WRicnH0JI1q[3KxZ3zpZUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGDNRU1{fGmvdXzheIVlKFS[QkKgdoVt\WG|ZTDwdoVqdmO3YnH0[YQh\m:{IEG1JI1qdnNibXXhd5Vz\WRiN{CgcYlveyCjZoTldkBRVUFiY3jhcIxmdmenLDDJR|UxRTNwMUNOwG0> NFnTXZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1N|g4PCd-MkKxOVM5PzR:L3G+
HCT116 NEjxPI9HfW6ldHnvckBie3OjeR?= MYSxJI1O NWG2c5NrPiCqcoO= NEfqXG5KdmirYnn0bY9vKG:oIGTOSk1idHCqYT3pcoR2[2WmIF7GMYtieHCjQjDhZ5RqfmG2aX;uJIlvKGi3bXHuJGhEXDFzNjDj[YxteyCjdDCxJI1OKGGodHXyJFYhcHK|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigQ>? NHfyeoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1OFg{PCd-MkKxOVQ5OzR:L3G+
SKBR3 M1y2PGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MW[zNFAhfU1? NF7LV3U1QCCqcoO= NYKxZYEyT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW0uEUkOgZ4VtdHNiYYSgN|AxKHWPIHHmeIVzKDR6IHjyd{BjgSCjbHHtZZIh[my3ZTDhd5NigQ>? MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR7NE[xO{c,OjJ2OUS2NVc9N2F-
PANC1 NFTDbZVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYj0VGZ[OzByIIXN M{P3T|Q5KGi{cx?= MXPHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDQRW5EOSClZXzsd{BifCB|MECgeW0h[W[2ZYKgOFghcHK|IHL5JIFt[W2jcjDicJVmKGG|c3H5 MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR7NE[xO{c,OjJ2OUS2NVc9N2F-
PC3 NFWxXVBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUmwboRvOzByIIXN MYS0PEBpenN? MUfHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDQR|Mh[2WubIOgZZQhOzByIIXNJIFnfGW{IES4JIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeR?= NHXieWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS5OFYyPyd-MkK0PVQ3OTd:L3G+
MDA-MB-231 MUjGeY5kfGmxbjDhd5NigQ>? NYjvZXpzOTByIIXN Mn7IN|AhdWmwcx?= MkjBTZJz\X[ncoPpZoxmKGmwaHnibZRqd25ib3[gR29ZNTFiaX6gbJVu[W5iTVTBMW1DNTJ|MTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGG{YXPobYRwdmmlIHHjbYQucW6mdXPl[EBRT0V{IH\vdo1ifGmxbjDheEAyODBidV2gbY5kfWKjdHXkJIZweiB|MDDtbY5{KG[xbHzve4VlKGK7IHPvcZBwfW6mIIfhd4hwfXRibXXhd5Vz\WRiM{CgcYlveyCyb4P0JIFz[WOqaXTvcolkKGGlaXSgZ4hidGynbnflJIJ6KHKjZHnvbY1ufW6xYYPzZZk> NHvrdY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[1NVM2QSd-MkO2OVE{PTl:L3G+
THP1 NGrWXmhHfW6ldHnvckBie3OjeR?= NH:5c3IyODBidV2= M3LjbVMxKG2rboO= M1Ty[mlzemW4ZYLzbYJt\SCrbnjpZol1cW:wIH;mJGNQYC1zIHnuJIh2dWGwIGTIVFEh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDhdoFkcGmmb37pZ{Bi[2mmLXnu[JVk\WRiVGjCNkBnd3KvYYTpc44h[XRiMUCwJJVOKGmwY4XiZZRm\CCob4KgN|AhdWmwczDmc4xtd3enZDDifUBkd22yb4Xu[EB4[XOqb4X0JI1m[XO3cnXkJFMxKG2rboOgdI9{fCCjcnHjbIlld26rYzDhZ4llKGOqYXzs[Y5o\SCkeTDyZYRqd2mvbYXuc4F{e2G7 M{nyfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkWxN|U6Lz5{M{[1NVM2QTxxYU6=
HCT116 M3;qZ2N6fG:2b4jpZ4l1gSCjc4PhfS=> MV60PEBpenN? M1;kTWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiNEigbJJ{KE2WVDDhd5NigQ>? M{H6UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{WwOFAyLz5{Nke1NFQxOTxxYU6=
H9c2 MlPtR4Fz\GmxcILveIVkfGm4ZTDhd5NigQ>? NYDYO4x[OSC3TR?= M4DWcFghcHK| NIXsVVJE[XKmaX;wdo91\WO2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJlxd3irYT3pcoR2[2WmIH;4bYRifGm4ZTDzeJJme3NibXXkbYF1\WRiaX7mcIFudWG2aX;uJIlvKHKjdDDIPYMzKGOnbHzzJIF{e2W|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJGlNNTZiaX6gd5Vx\XKwYYThcpQh[XRiMTD1UUBxemWrbnP1ZoF1\WRiZn;yJFghcHK|IH\vcIxwf2WmIHL5JGgzVzJiYXTkbZRqd25iZn;yJFIhcHK|IHL5JGVNUVOD NVH6RVY1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke1O|U1PzFpPkK3OVc2PDdzPD;hQi=>
H9c2 NF\hZmpE[XKmaX;wdo91\WO2aY\lJIF{e2G7 NFf2V|EyKHWP MYC4JIhzew>? NV;Sc2lnS2G{ZHnvdJJwfGWldHn2[UBi[3Srdnn0fUBi\2GrboP0JIh6eG:6aXGtbY5lfWOnZDDvfIll[XSrdnWgd5Rz\XO|IH3l[IlifGWmIHnu[oxidW2jdHnvckBqdiC{YYSgTFlkOiClZXzsd{Bie3Onc4Pl[EBieyC|dYDwdoV{e2mxbjDv[kBVVkZvYXzwbIEhcW5ic4Xw[ZJv[XSjboSgZZQhOSC3TTDwdoVqdmO3YnH0[YQh\m:{IEigbJJ{KG[xbHzve4VlKGK7IFiyU|Ih[WSmaYTpc44h\m:{IEKgbJJ{KGmwIIDy[ZNmdmOnIH;mJIxmd263cnnu[UBjgSCH M4PoXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NUe1OFcyLz5{N{W3OVQ4OTxxYU6=
H9c2 MWLDZZJlcW:ycn;0[YN1cX[nIHHzd4F6 NIPnRZMyKHWP MXm4JIhzew>? NGj0eotE[XKmaX;wdo91\WO2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJlxd3irYT3pcoR2[2WmIH;4bYRifGm4ZTDzeJJme3NiaX6gdoF1KEh7Y{KgZ4VtdHNiYYPz[ZN{\WRiYYOgZY51cW:6aXThcpQh[WO2aY\peJkh[nlibXXhd5VzcW6pIILl[JVkfGmxbjDpckBOTEFibHX2[Yx{KGG2IEGgeW0heHKnaX7jeYJifGWmIH\vdkA5KGi{czDmc4xtd3enZDDifUBJOk9{IHHk[Il1cW:wIH\vdkAzKGi{czDifUB{eGWldILvdIhwfG:vZYTyfS=> M4nGXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NUe1OFcyLz5{N{W3OVQ4OTxxYU6=
H9c2 MV7DZZJlcW:ycn;0[YN1cX[nIHHzd4F6 MWSxJJVO MlPsPEBpenN? MWrDZZJlcW:ycn;0[YN1cX[nIHHjeIl3cXS7IHHnZYlve3RiaInwc5hq[S2rbnT1Z4VlKG:6aXTheIl3\SC|dILld5MhcW5icnH0JGg6[zJiY3XscJMh[XO|ZYPz[YQh[XNiYX70bY95cWSjboSgZYN1cX[rdImgZpkhdWWjc4XybY5oKGmwY4LlZZNmKGmwIGPPSEBi[3Srdnn0fUBifCBzIIXNJJBz\WmwY4XiZZRm\CCob4KgPEBpenNiZn;scI94\WRiYomgTFJQOiCjZHTpeIlwdiCob4KgNkBpenNiYomgd5Bm[3S{b4Doc5RwdWW2com= MnrSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3N{W0O|EoRjJ5NUe1OFcyRC:jPh?=
H9c2 NGeyTYxE[XKmaX;wdo91\WO2aY\lJIF{e2G7 MUWxJJVO NGr6Toc5KGi{cx?= MW\DZZJlcW:ycn;0[YN1cX[nIHHjeIl3cXS7IHHnZYlve3RiaInwc5hq[S2rbnT1Z4VlKG:6aXTheIl3\SC|dILld5MhcW5icnH0JGg6[zJiY3XscJMh[XO|ZYPz[YQh[XNiYX70bY95cWSjboSgZYN1cX[rdImgZpkhdWWjc4XybY5oKGmwY4LlZZNmKGmwIHPheIFt[XOnIHHjeIl3cXS7IHH0JFEhfU1icILlbY5kfWKjdHXkJIZweiB6IHjyd{Bnd2yub4fl[EBjgSCKMl:yJIFl\Gm2aX;uJIZweiB{IHjyd{BjgSC|cHXjeJJweGixdH;t[ZRzgQ>? M3\xRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NUe1OFcyLz5{N{W3OVQ4OTxxYU6=
H9c2 MkHIR4Fz\GmxcILveIVkfGm4ZTDhd5NigQ>? MVqxJJVO NIHQdFk5KGi{cx?= NW\MNHV3S2G{ZHnvdJJwfGWldHn2[UBi[3Srdnn0fUBi\2GrboP0JIh6eG:6aXGtbY5lfWOnZDDvfIll[XSrdnWgd5Rz\XO|IH3l[IlifGWmIHnu[oxidW2jdHnvckBqdiC{YYSgTFlkOiClZXzsd{Bie3Onc4Pl[EBieyC|dYDwdoV{e2mxbjDv[kBVVkZvYXzwbIEhcW5ic4Xw[ZJv[XSjboSgZZQhOSC3TTDwdoVqdmO3YnH0[YQh\m:{IEigbJJ{KG[xbHzve4VlKGK7IFiyU|Ih[WSmaYTpc44h\m:{IEKgbJJ{KGK7IFXMTXNC MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzV5NUS3NUc,Ojd3N{W0O|E9N2F-
H9c2 NFrQZmxE[XKmaX;wdo91\WO2aY\lJIF{e2G7 NFLPencyKHWP NGDZWJM5KGi{cx?= MmfnR4Fz\GmxcILveIVkfGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj5dI95cWFvaX7keYNm\CCxeHnkZZRqfmVic4Ty[ZN{KG2nZHnheIVlKGmwZnzhcY1ifGmxbjDpckBz[XRiSEnjNkBk\WyuczDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjDJUE0y[mW2YTDpckB{fXCncn7heIFvfCCjdDCxJJVOKHC{ZXnuZ5Vj[XSnZDDmc5IhQCCqcoOg[o9tdG:5ZXSgZpkhUDKRMjDh[IRqfGmxbjDmc5IhOiCqcoOgZpkhTUyLU1G= M4rSRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NUe1OFcyLz5{N{W3OVQ4OTxxYU6=
H9c2 NUX5bph5S2G{ZHnvdJJwfGWldHn2[UBie3OjeR?= MkDnNUB2VQ>? M3HxRlghcHK| Mkf0R4Fz\GmxcILveIVkfGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj5dI95cWFvaX7keYNm\CCxeHnkZZRqfmVic4Ty[ZN{KGmwIILheEBJQWN{IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBOTEFibHX2[Yx{KGG2IEGgeW0heHKnaX7jeYJifGWmIH\vdkA5KGi{czDmc4xtd3enZDDifUBJOk9{IHHk[Il1cW:wIH\vdkAzKGi{czDpckBxemW|ZX7j[UBw\iCuZX;ueZJqdmViYomgd5Bm[3S{b4Doc5RwdWW2com= NV7WTYFGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke1O|U1PzFpPkK3OVc2PDdzPD;hQi=>
H9c2 MUPDZZJlcW:ycn;0[YN1cX[nIHHzd4F6 MWexJJVO NH\NbW45KGi{cx?= NY\FWIh5S2G{ZHnvdJJwfGWldHn2[UBi[3Srdnn0fUBi\2GrboP0JIh6eG:6aXGtbY5lfWOnZDDvfIll[XSrdnWgd5Rz\XO|IHnuJJJifCCKOXOyJINmdGy|IHHzd4V{e2WmIHHzJIFvfGmxeHnkZY51KGGldHn2bZR6KGK7IH3lZZN2emmwZzDpcoNz\WG|ZTDpckBUV0RiYXP0bZZqfHliYYSgNUB2VSCycnXpcoN2[mG2ZXSg[o9zKDhiaILzJIZwdGyxd3XkJIJ6KEh{T{KgZYRlcXSrb36g[o9zKDJiaILzJIlvKHC{ZYPlcoNmKG:oIHzlc452emmwZTDifUB{eGWl MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzV5NUS3NUc,Ojd3N{W0O|E9N2F-
H9c2 MmmxR4Fz\GmxcILveIVkfGm4ZTDhd5NigQ>? NFnVPVAyKHWP NHTRSos5KGi{cx?= M3LXXWNiemSrb4Dyc5Rm[3SrdnWgZYN1cX[rdImgZYdicW6|dDDofZBwgGmjLXnu[JVk\WRib4jp[IF1cX[nIIP0doV{eyCvZXTpZZRm\CCrbn\sZY1u[XSrb36gbY4hemG2IFi5Z|Ih[2WubIOgZZN{\XO|ZXSgZZMhe3WycILld5Nqd25ib3[gTWwuPiCrbjDzeZBmem6jdHHueEBifCBzIIXNJJBz\WmwY4XiZZRm\CCob4KgPEBpenNiZn;scI94\WRiYomgTFJQOiCjZHTpeIlwdiCob4KgNkBpenNiaX6gdJJme2WwY3Wgc4YhdGWxboXybY5mKGK7IFXMTXNC MlvrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3N{W0O|EoRjJ5NUe1OFcyRC:jPh?=
H9c2 NFe1c4tE[XKmaX;wdo91\WO2aY\lJIF{e2G7 MluzNUB2VQ>? M2Hx[FghcHK| Ml\1R4Fz\GmxcILveIVkfGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj5dI95cWFvaX7keYNm\CCxeHnkZZRqfmVic4Ty[ZN{KG2nZHnheIVlKGmwZnzhcY1ifGmxbjDpckBz[XRiSEnjNkBk\WyuczDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjDJUE0y[mW2YTDpckB{fXCncn7heIFvfCCjdDCxJJVOKHC{ZXnuZ5Vj[XSnZDDmc5IhQCCqcoOg[o9tdG:5ZXSgZpkhUDKRMjDh[IRqfGmxbjDmc5IhOiCqcoOgbY4heHKnc3XuZ4Uhd2ZibHXvcpVzcW6nIHL5JGVN M{n3c|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NUe1OFcyLz5{N{W3OVQ4OTxxYU6=
H9c2 NWTIfZUzS2G{ZHnvdJJwfGWldHn2[UBie3OjeR?= MUKxJJVO M4jRR|ghcHK| M4HoemNiemSrb4Dyc5Rm[3SrdnWgZYN1cX[rdImgZYdicW6|dDDofZBwgGmjLXnu[JVk\WRiY4n0c5RwgGmlaYT5JIlvKHKjdDDIPYMzKGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGG2IEGgeW0heHKnaX7jeYJifGWmIH\vdkA5KGi{czDmc4xtd3enZDDifUBJOk9{IHHk[Il1cW:wIH\vdkAzKGi{czDifUBOXFRiYYPzZZk> MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzV5NUS3NUc,Ojd3N{W0O|E9N2F-
RAW264.7 NIjhV|lCdnSraX7mcIFudWG2b4L5JIF{e2G7 MmTsRY51cWmwZnzhcY1ifG:{eTDhZ5Rqfmm2eTDpckBud3W|ZTDSRXczPjRwNzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEySUz3pcoR2[2WmIH7peJJq[yCxeHnk[UBxem:mdXP0bY9vKGK7IH3lZZN2emmwZzDubZRzcXSnIHHjZ5VufWyjdHnvckBjgSCJcnnld5MhdWW2aH;kMEBKSzVyPUSzMlLPxE1? NYXnVGxXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OlE2QDZpPkK4OVYyPTh4PD;hQi=>
stem cells NGLKfFhHfW6ldHnvckBie3OjeR?= MWKxNFAhfU1? NVW1[5lZPSCmYYnz NXntVldqUW6mdXP0bY9vKG:oIHHkbZBw\2WwZYPpd{BqdiCqdX3hckBjd26nIH3hdpJwfy2mZYLpeoVlKG2nc3XuZ4h6dWGuIIP0[Y0h[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iYXTpdI9v\WO2aX6gdJJw\HWldHnvckBifCBzMECgeW0hdWWjc4Xy[YQhd25iZHH5JFUhcW5icILld4Vv[2Vib3[gTWRZKGK7IFXMTXNC MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTN7OES0N{c,Ojl|OUi0OFM9N2F-
DAOY NYfWWGFoeUiWUzDhd5NigQ>? NYrUZ|A1eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO= Mm\0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh30 NHH2RZFyUFSVIHHzd4F6 NGTmRVhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnizNEBk\Wyucx?= MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh41 NITBSWlyUFSVIHHzd4F6 NILHOIpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?= MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
peritoneal cells NXXwZogyTnWwY4Tpc44h[XO|YYm= Mmq3OUBpenN? M{L4XGlvcGmkaYTpc44hd2ZiTGDTMYlv\HWlZXSgVGdGOiCycn;keYN1cW:wIHnuJGM2P0KONjDtc5V{\SCyZYLpeI9v\WGuIHPlcIx{KG2nYYP1doVlKGG2IEWgbJJ{KHSrbXWgbY51\XK4YXygZpkhTUyLU1GsJGlEPTB;ND6wPO69VQ>? NX74XFdURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwNFYyPzJpPkOwNFA3OTd{PD;hQi=>
HCT8 M4jM[2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 NUHLVGI1PzJiaILz NVK4VVVkSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3Q5KGOnbHzzJIFnfGW{IEeyJIhzeyCrbjDwdoV{\W6lZTDv[kBkcW6wYX3hcIRmcHmmZTDifUBOXFRiYYPzZZktKEmFNUC9NVUvPs7:TR?= M2XUbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEO3OFk1Lz5|MECzO|Q6PDxxYU6=
RPMI8226 NYfwSIdGS2WubDDjfYNt\SCjc4PhfS=> NH[0[YkyNjdidV2= MVu0PEBpenN? NF;xcmRE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBTWE2LOEKyOkBk\WyuczDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgS|AwTzFicHjhd4Uh[XRiMT63JJVOKGmwIIDy[ZNmdmOnIH;mJIJwenSnen;tbYIh[W[2ZYKgOFghcHK|IHL5JJBzd3CrZHn1cUBqd2SrZHWvVm5ie2Vic4ThbY5qdmdiYnHz[YQh\myxdzDjfZRwdWW2cnnjJI1mfGixZDDy[YxifGm4ZTD0c{Bjd3K2ZYrvcYlj MknkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB3OUCyOVgoRjNyNUmwNlU5RC:jPh?=
RPMI8226 MljVR4VtdCCleXPs[UBie3OjeR?= MoLFNU44KHWP NITxVmU1QCCqcoO= MVjD[YxtKGO7Y3zlJIFzemW|dDDpckBpfW2jbjDSVG1KQDJ{NjDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiUzDwbIF{\SCjdDCxMlchfU1iaX6gdJJme2WwY3Wgc4Yh[m:{dHX6c41q[iCjZoTldkA1QCCqcoOgZpkheHKxcHnkbZVuKGmxZHnk[U9TVmG|ZTDzeIFqdmmwZzDiZZNm\CCobH;3JIN6fG:vZYTybYMhdWW2aH;kJJJmdGG2aY\lJJRwKGKxcoTlfo9ucWJ? NX\LVW1MRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C1PVAzPThpPkOwOVkxOjV6PD;hQi=>
RPMI8226 M{nlfWNmdGxiY4njcIUh[XO|YYm= MU[xMlchfU1? M3zxUFQ5KGi{cx?= MlLuR4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gVnBOUTh{Mk[gZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGGlY4XteYxifGmxbjDheEBIOi:PIIDoZZNmKGG2IEGuO{B2VSCrbjDwdoV{\W6lZTDv[kBjd3K2ZYrvcYljKGGodHXyJFQ5KGi{czDifUBxem:yaXTpeY0hcW:maXTlM3JP[XOnIIP0ZYlvcW6pIHLhd4VlKG[ub4egZ5l1d22ndILpZ{Bu\XSqb3SgdoVt[XSrdnWgeI8h[m:{dHX6c41q[g>? NIrYTJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEW5NFI2QCd-M{C1PVAzPTh:L3G+
HaCaT NH[wTXNCdnSrcIny[ZRq[yCjc4PhfS=> NFTDUokyODBidV2= NXW4U5VqOiCqcoO= MoPLRY51cXC7cnX0bYMh[WO2aY\peJkhcW5iaIXtZY4hUGGFYWSgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCWTl\hcJBp[S2rbnT1Z4VlKFCJRUKgdJJw\HWldHnvckBifCBzMECgeW0heHKnLXnuZ5Vj[XSnZDDmc5IhOiCqcoOgZoVnd3KnIGTOSoFteGijIIP0bY12dGG2aX;uJIZweiB{NDDodpMh[nliRVzJV2E> MlzEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF|OUOxNlUoRjNzM{mzNVI2RC:jPh?=
OVCAR5 M{\WSmZ2dmO2aX;uJIF{e2G7 M1vHW|MxOCC3TTD0c{AyKG2P NFjYPYg4OiCqcoO= M2XKVGlvcGmkaYTpc44hd2ZiTlHQVnQhcW5iaIXtZY4hV1[FQWK1JINmdGy|IHHzd4V{e2WmIHHzJJBwfGWwdHnheIlwdiCxZjDORW1RXCCrbnjpZol1d3JiRlu4OlYucW6mdXPl[EBkgXSxdH;4bYNqfHliYomgcYVie3W{aX7nJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBifCB|MECgeW0hfG9iMTDtUUBqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDTVmIh[XO|YYm= NEXZN4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPS9pPlPoSW1DVDxxYU6=
CCRF-CEM NVO5WlZSTnWwY4Tpc44h[XO|YYm= NU\iNW0xOy53IH3N M{TRUFQ5KGi{cx?= Ml[xTY5pcWKrdHnvckBw\iCQQWDSWEBqdiCqdX3hckBES1KILVPFUUBk\WyuczDhd5Nme3OnZDDhd{Bxd3SnboTpZZRqd25ib3[gUmFOWFRiaX7obYJqfG:{IF\LPFY3NWmwZIXj[YQh[XCxcITvd4l{KGK7IH3lZZN2emmwZzDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZZQhOy53IH3NJJBz\XJvaX7jeYJifGWmIIfpeIghUUN3MDDs[ZZmdCCxZjDGT|g3PiCob4KgOFghcHK|IH\vcIxwf2WmIHL5JINwdXCxdX7kJIFl\Gm2aX;uJIFv\CCodYL0bIVz NVjw[JpERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjVxJ{7DbGVOSkx:L3G+
Jurkat NW\4Z2RMTnWwY4Tpc44h[XO|YYm= NWi0T|J{Oy53IH3N MoHEOFghcHK| NVjwOotpUW6qaXLpeIlwdiCxZjDORXBTXCCrbjDoeY1idiCMdYLrZZQh[2WubIOgZZN{\XO|ZXSgZZMheG:2ZX70bYF1cW:wIH;mJG5CVVCWIHnubIljcXSxcjDGT|g3Pi2rbnT1Z4VlKGGyb4D0c5NqeyCkeTDt[YF{fXKrbnegdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIF1KDNwNTDtUUBxemW{LXnuZ5Vj[XSnZDD3bZRpKEmFNUCgcIV3\Wxib3[gSms5PjZiZn;yJFQ5KGi{czDmc4xtd3enZDDifUBkd22yb4Xu[EBi\GSrdHnvckBidmRiZoXyeIhmeiCr MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOU8oRkOqRV3CUFww[T5?
ML2 M4XvbGZ2dmO2aX;uJIF{e2G7 NHLoXpM{NjVibV2= MoTvOFghcHK| MmLwTY5pcWKrdHnvckBw\iCQQWDSWEBqdiCqdX3hckBOVDJiY3XscJMh[XO|ZYPz[YQh[XNicH;0[Y51cWG2aX;uJI9nKE6DTWDUJIlvcGmkaYTvdkBHUzh4Nj3pcoR2[2WmIHHwc5B1d3OrczDifUBu\WG|dYLpcochemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGG2IEOuOUBuVSCycnXyMYlv[3WkYYTl[EB4cXSqIFnDOVAhdGW4ZXygc4YhTkt6Nk[g[o9zKDR6IHjyd{Bnd2yub4fl[EBjgSClb33wc5Vv\CCjZHTpeIlwdiCjbnSg[pVzfGincjDpcoN2 NGLFN5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPS9pPlPoSW1DVDxxYU6=
NOMO M4nUUGZ2dmO2aX;uJIF{e2G7 MYSzMlUhdU1? MkL6OFghcHK| NIDZeG1KdmirYnn0bY9vKG:oIF7BVHJVKGmwIHj1cYFvKE6RTV:gZ4VtdHNiYYPz[ZN{\WRiYYOgdI91\W62aXH0bY9vKG:oIF7BUXBVKGmwaHnibZRweiCIS{i2Ok1qdmS3Y3XkJIFxd3C2b4Ppd{BjgSCvZXHzeZJqdmdicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHH0JFMvPSCvTTDwdoVzNWmwY4XiZZRm\CC5aYToJGlEPTBibHX2[Ywhd2ZiRlu4OlYh\m:{IES4JIhzeyCob3zsc5dm\CCkeTDjc41xd3WwZDDh[IRqfGmxbjDhcoQh\nW{dHjldkBqdmN? MmXMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlUwLz6FaFXNRmw9N2F-
NB4 MYTGeY5kfGmxbjDhd5NigQ>? NVTPd4ZbOy53IH3N MUC0PEBpenN? M1XKVGlvcGmkaYTpc44hd2ZiTlHQVnQhcW5iaIXtZY4hVkJ2IHPlcIx{KGG|c3Xzd4VlKGG|IIDveIVvfGmjdHnvckBw\iCQQV3QWEBqdmirYnn0c5IhTkt6Nk[tbY5lfWOnZDDhdI9xfG:|aYOgZpkhdWWjc4XybY5oKHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjdDCzMlUhdU1icILldk1qdmO3YnH0[YQhf2m2aDDJR|UxKGyndnXsJI9nKE[NOE[2JIZweiB2ODDodpMh\m:ubH;3[YQh[nliY3;tdI92dmRiYXTkbZRqd25iYX7kJIZ2enSqZYKgbY5kfQ>? Ml\VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlUwLz6FaFXNRmw9N2F-
NAMALWA Ml\SSpVv[3Srb36gZZN{[Xl? NHHDcHI{NjVibV2= NFnlTYo1QCCqcoO= MoiyTY5pcWKrdHnvckBw\iCQQWDSWEBqdiCqdX3hckBPSU2DTGfBJINmdGy|IHHzd4V{e2WmIHHzJJBwfGWwdHnheIlwdiCxZjDORW1RXCCrbnjpZol1d3JiRlu4OlYucW6mdXPl[EBieG:ydH;zbZMh[nlibXXhd5VzcW6pIILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDheEA{NjVibV2gdJJmei2rbnP1ZoF1\WRid3n0bEBKSzVyIHzleoVtKG:oIF\LPFY3KG[xcjC0PEBpenNiZn;scI94\WRiYomgZ49ueG:3bnSgZYRlcXSrb36gZY5lKG[3coTo[ZI> M{fMbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2Nyd-Q3jFUWJNRC:jPh?=
Daudi M4q2XWZ2dmO2aX;uJIF{e2G7 NWnl[XpjOy53IH3N NGW5[ZI1QCCqcoO= M321NmlvcGmkaYTpc44hd2ZiTlHQVnQhcW5iaIXtZY4hTGG3ZHmgZ4VtdHNiYYPz[ZN{\WRiYYOgdI91\W62aXH0bY9vKG:oIF7BUXBVKGmwaHnibZRweiCIS{i2Ok1qdmS3Y3XkJIFxd3C2b4Ppd{BjgSCvZXHzeZJqdmdicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHH0JFMvPSCvTTDwdoVzNWmwY4XiZZRm\CC5aYToJGlEPTBibHX2[Ywhd2ZiRlu4OlYh\m:{IES4JIhzeyCob3zsc5dm\CCkeTDjc41xd3WwZDDh[IRqfGmxbjDhcoQh\nW{dHjldkBqdg>? M4\iVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2Nyd-Q3jFUWJNRC:jPh?=
Raji MWrGeY5kfGmxbjDhd5NigQ>? NUXuVYNYOy53IH3N M3;JdVQ5KGi{cx?= MlPqTY5pcWKrdHnvckBw\iCQQWDSWEBqdiCqdX3hckBT[WqrIHPlcIx{KGG|c3Xzd4VlKGG|IIDveIVvfGmjdHnvckBw\iCQQV3QWEBqdmirYnn0c5IhTkt6Nk[tbY5lfWOnZDDhdI9xfG:|aYOgZpkhdWWjc4XybY5oKHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjdDCzMlUhdU1icILldk1qdmO3YnH0[YQhf2m2aDDJR|UxKGyndnXsJI9nKE[NOE[2JIZweiB2ODDodpMh\m:ubH;3[YQh[nliY3;tdI92dmRiYXTkbZRqd25iYX7kJIZ2enSqZYKgbY5k MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOU8oRkOqRV3CUFww[T5?
ARH77 MXfGeY5kfGmxbjDhd5NigQ>? MkmzN{42KG2P MoPYOFghcHK| NYX3UGpoUW6qaXLpeIlwdiCxZjDORXBTXCCrbjDoeY1idiCDUli3O{Bk\WyuczDhd5Nme3OnZDDhd{Bxd3SnboTpZZRqd25ib3[gUmFOWFRiaX7obYJqfG:{IF\LPFY3NWmwZIXj[YQh[XCxcITvd4l{KGK7IH3lZZN2emmwZzDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZZQhOy53IH3NJJBz\XJvaX7jeYJifGWmIIfpeIghUUN3MDDs[ZZmdCCxZjDGT|g3PiCob4KgOFghcHK|IH\vcIxwf2WmIHL5JINwdXCxdX7kJIFl\Gm2aX;uJIFv\CCodYL0bIVzKGmw NGmzdZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPS9pPlPoSW1DVDxxYU6=
RPMI8226 Mmf5SpVv[3Srb36gZZN{[Xl? MYSzMlUhdU1? NVH5cWZbPDhiaILz NIDGRpRKdmirYnn0bY9vKG:oIF7BVHJVKGmwIHj1cYFvKFKSTVm4NlI3KGOnbHzzJIF{e2W|c3XkJIF{KHCxdHXueIlifGmxbjDv[kBPSU2SVDDpcohq[mm2b4KgSms5PjZvaX7keYNm\CCjcH;weI9{cXNiYomgcYVie3W{aX7nJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBifCB|LkWgcW0heHKncj3pcoN2[mG2ZXSge4l1cCCLQ{WwJIxmfmWuIH;mJGZMQDZ4IH\vdkA1QCCqcoOg[o9tdG:5ZXSgZpkh[2:vcH;1coQh[WSmaYTpc44h[W6mIH\1dpRp\XJ? NWHUeJk2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjVxJ{7DbGVOSkx:L3G+
U266 NFvBOZJHfW6ldHnvckBie3OjeR?= M3rPdFMvPSCvTR?= MU[0PEBpenN? MmXkTY5pcWKrdHnvckBw\iCQQWDSWEBqdiCqdX3hckBWOjZ4IHPlcIx{KGG|c3Xzd4VlKGG|IIDveIVvfGmjdHnvckBw\iCQQV3QWEBqdmirYnn0c5IhTkt6Nk[tbY5lfWOnZDDhdI9xfG:|aYOgZpkhdWWjc4XybY5oKHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjdDCzMlUhdU1icILldk1qdmO3YnH0[YQhf2m2aDDJR|UxKGyndnXsJI9nKE[NOE[2JIZweiB2ODDodpMh\m:ubH;3[YQh[nliY3;tdI92dmRiYXTkbZRqd25iYX7kJIZ2enSqZYKgbY5k M3jFc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2Nyd-Q3jFUWJNRC:jPh?=
NAMALWA Moq2SpVv[3Srb36gZZN{[Xl? MkjKN|UhdWdxa3e= M3Hse|Q2KGSjeYO= MYnQc5RmdnSrYYTpc44hd2ZiTlHNVHQhcW6qaXLpeI9zKDFyIH3nM4toNCCrcDDibYQhTkt6Nk[tbY5lfWOnZDDhcpRqfHWvb4KgZYN1cX[rdImgbY4hcHWvYX6gUmFOSUyZQTDj[YxteyC6ZX7v[5Ji\nSnZDDpckBUS0mGIH3veZNmKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJI1wfXOnIIP1dpZqfmGuIHH0JFM2KG2pL3vnMEBqeCCkaXSgeZAhfG9iNEWg[IF6ew>? M2LoclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2Nyd-Q3jFUWJNRC:jPh?=
Assay
Methods Test Index PMID
Western blot SHH / SMO / GLI1 / Bcl-2 / Foxm1 ; ; p-AMPKα / AMPKα / p-ACC / ACC ; p-AKT / AKT / p-ERK / ERK ; MCL-1 28446712 23741443 26918349
Growth inhibition assay Cell viability ; Cell proliferation 30221683 28446712

Protocol (from reference)

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
4% DMSO+PBS
For best results, use promptly after mixing.

10mg/mL

Chemical Information

Molecular Weight 180.16
Formula

C9H8O4

CAS No. 50-78-2
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(=O)OC1=CC=CC=C1C(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04563546 Not yet recruiting Other: Quality Improvement Acute Coronary Syndrome Duke University January 1 2023 Not Applicable
NCT05411718 Not yet recruiting Drug: Naproxen|Drug: Aspirin T Cells|Colorectal Cancer|Lynch Syndrome M.D. Anderson Cancer Center|National Institutes of Health (NIH)|National Cancer Institute (NCI) November 25 2022 Phase 2
NCT05198960 Recruiting Drug: Direct Oral Anticoagulants|Drug: Low-dose aspirin Polycythemia Vera|Essential Thrombocythemia|Prefibrotic/Early Primary Myelofibrosis|JAK2 V617F|High-risk Patients University Hospital Brest July 2022 Phase 3
NCT05257824 Recruiting Drug: Aspirin 100mg|Drug: Clopidogrel 75mg Aneurysm Cerebral|Endovascular Procedures Seoul National University Bundang Hospital|Soonchunhyang University Hospital|Soonchunhyang University Cheonan Hospital|Seoul National University Hospital|Pusan National University Yangsan Hospital|Keimyung University Dongsan Medical Center|Seoul St. Mary''s Hospital|Uijeongbu St. Mary''s Hospital|Ajou University School of Medicine|Chungnam National University Sejong Hospital|Severance Hospital|Asan Medical Center|Yonsei University Gangnam Severance Hospital June 23 2022 Phase 4

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Aspirin (NSC 27223) | Aspirin (NSC 27223) supplier | purchase Aspirin (NSC 27223) | Aspirin (NSC 27223) cost | Aspirin (NSC 27223) manufacturer | order Aspirin (NSC 27223) | Aspirin (NSC 27223) distributor